Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioporto ASTHOXF 68 1-Year Share Buyback Ratio is -15.20 as of Jun. 2026. GuruFocus rates THOXF with a GF Score™ of 68/100 and a GF Value™ of $0.14. The stock has 5 warning signs investors should review. Among 147 Medical Diagnostics & Research companies, Bioporto AS ranks worse than 66.67% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Bioporto AS's current 1-Year Share Buyback Ratio was -15.20%.
THOXF's 1-Year Share Buyback Ratio is ranked worse than 66.67% of 147
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.9
vs THOXF: -15.20
Bioporto AS (OTCPK:THOXF) 1-Year Share Buyback Ratio Explanation
A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Bioporto AS 1-Year Share Buyback Ratio Related Terms
THOXF vs TMO, DHR, IDXX: 1-Year Share Buyback Ratio Comparison
For the Diagnostics & Research subindustry, Bioporto AS's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioporto AS 1-Year Share Buyback Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's 1-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Bioporto AS's 1-Year Share Buyback Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 1-Year Share Buyback Ratio of -15.20 mean?
Bioporto AS (THOXF) has a 1-Year Share Buyback Ratio of -15.20 as of Jun. 2026. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Bioporto AS and its competitors. According to the industry distribution chart, Bioporto AS ranks #98 out of 147 companies in the Medical Diagnostics & Research industry, placing it in the top 66.7%.
Is Bioporto AS's 1-Year Share Buyback Ratio too high?
Bioporto AS's current 1-Year Share Buyback Ratio is -15.20. Based on the distribution chart, Bioporto AS ranks #98 out of 147 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Bioporto AS has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's 1-Year Share Buyback Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #98 out of 147 companies for 1-Year Share Buyback Ratio. This places Bioporto AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Medical Diagnostics & Research company?
A good 1-Year Share Buyback Ratio depends on the Medical Diagnostics & Research industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Bioporto AS and its competitors. Bioporto AS's current 1-Year Share Buyback Ratio is -15.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (THOXF) has a current 1-Year Share Buyback Ratio of -15.20. The stock's GF Value™ is $0.14, compared to a current price of $0.15 — trading 6.4% above its estimated fair value. The current 1-Year Share Buyback Ratio is -15.20. Bioporto AS's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For Bioporto AS (THOXF), the current 1-Year Share Buyback Ratio is -15.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (THOXF) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be overvalued.
The current stock price of $0.15 is trading 6.4% above its estimated GF Value™ of $0.14.
Key valuation signals for THOXF:
1-Year Share Buyback Ratio: -15.20
GF Value™: $0.14 vs. price of $0.15 (6.4% above fair value)
No single metric tells the full story. See the THOXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
68GF Score
Get the complete analysis for THOXF
1-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
THOXF has been successfully added to your 
